Dennis E. Hallahan
YOU?
Author Swipe
View article: Supplementary Figure S7 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S7 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 7. Biophysical characterization of the purified L111 antibody. A. Analysis of purified L111 antibody integrity by non-reduced (top) and reduced (bottom) capillary electrophoresis-SDS (CE-SDS) on a Perkin Elmer LabChip …
View article: Data from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Data from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Purpose:Tax-interacting protein 1 (TIP1) is a cancer-specific radiation-inducible cell surface antigen that plays a role in cancer progression and resistance to therapy. This study aimed to develop a novel anti-TIP1 human antibody for noni…
View article: Supplementary Figure S12 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S12 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 12. In vitro characterization of [89Zr]Zr-DFO-L111. A. SDS-PAGE under non-reducing and reducing conditions for the [89Zr]Zr-DFO-L111 developed by autoradiography. Four two-fold dilutions were loaded on the SDS-PAGE gel…
View article: Supplementary Figure S3 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S3 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 3. A. Representative chromatogram showing protein A purification profile of the L111 antibody. B. Representative size exclusion chromatogram in S200 10/300 GL columns of the purified L111 antibody.
View article: Supplementary Figure S9 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S9 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 9. A. HPLC-SEC analysis of L111 and L111-DFO on an Agilent 1200 series HPLC system using a Zorbax GF-250 9.4 mm ID x 25 cm column (Agilent). DFO conjugation did not change the retention time of the antibody, and no agg…
View article: Supplementary Figure S13 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S13 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 13. A. Schematic representation of the tumor implantation, irradiation, antibody injection, PET imaging and post-PET biodistribution schedule. B and C. The tumor SUV max in H460 tumors (B) and A549 tumors (C) at days 2…
View article: Supplementary Table S1 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Table S1 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Table 1. Rank ordering of the anti-TIP1 antibodies based on their KD values
View article: Supplementary Figure S10 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S10 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 10. A. In vitro stability of [89Zr]Zr-DFO-L111 antibodies that were either freshly conjugated with DFO or thawed from -80°C after DFO conjugation. The stability was assessed in human serum by instant thin-layer chromat…
View article: Supplementary Figure S1 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S1 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 1. Strategy for WashU II phage display library creation. The human antibody repertoires were amplified by PCR from the cDNA of mixed human peripheral blood mononuclear cells and cloned randomly into a phagemid vector. …
View article: Supplementary Figure S6 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S6 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 6. Flow cytometry evaluation of the purified anti-TIP1 antibodies on H460 (A) and A549 (B) cells. The percentage of anti-TIP1+ vs. antibody concentration was plotted in GraphPad Prism software using One Site-specific b…
View article: Supplementary Figure S13 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S13 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 13. A. Schematic representation of the tumor implantation, irradiation, antibody injection, PET imaging and post-PET biodistribution schedule. B and C. The tumor SUV max in H460 tumors (B) and A549 tumors (C) at days 2…
View article: Supplementary Figure S8 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S8 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 8. DFO-to-L111 ratio (DAR) analysis by native MS. The deconvoluted mass spectra (deconvoluted using Intact Mass, Protein Metrics Inc) show the increasing numbers of DFO (+1 to +8). The respective DARs are shown in red.
View article: Supplementary Figure S11 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S11 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 11. Specific uptake of the [89Zr]Zr-DFO-L111 in tumors in vivo. Bar graph showing the uptake of the [89Zr]Zr-DFO-Isotype or [89Zr]Zr-DFO-L111 at days 2 and 5 in nude mice bearing A549 tumors in the hindlimb (n=4). Tumo…
View article: Supplementary Table S2 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Table S2 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Table 2. The analysis of the DFO-to-antibody ratio for the D10-L111 by native mass spectrometry
View article: Supplementary Figure S12 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S12 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 12. In vitro characterization of [89Zr]Zr-DFO-L111. A. SDS-PAGE under non-reducing and reducing conditions for the [89Zr]Zr-DFO-L111 developed by autoradiography. Four two-fold dilutions were loaded on the SDS-PAGE gel…
View article: Supplementary Figure S11 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S11 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 11. Specific uptake of the [89Zr]Zr-DFO-L111 in tumors in vivo. Bar graph showing the uptake of the [89Zr]Zr-DFO-Isotype or [89Zr]Zr-DFO-L111 at days 2 and 5 in nude mice bearing A549 tumors in the hindlimb (n=4). Tumo…
View article: Supplementary Table S3 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Table S3 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Table 3. Rank ordering of the DFO conjugated L111 antibodies based on their KD values
View article: Data from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Data from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Purpose:Tax-interacting protein 1 (TIP1) is a cancer-specific radiation-inducible cell surface antigen that plays a role in cancer progression and resistance to therapy. This study aimed to develop a novel anti-TIP1 human antibody for noni…
View article: Supplementary Figure S9 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S9 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 9. A. HPLC-SEC analysis of L111 and L111-DFO on an Agilent 1200 series HPLC system using a Zorbax GF-250 9.4 mm ID x 25 cm column (Agilent). DFO conjugation did not change the retention time of the antibody, and no agg…
View article: Supplementary Figure S8 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S8 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 8. DFO-to-L111 ratio (DAR) analysis by native MS. The deconvoluted mass spectra (deconvoluted using Intact Mass, Protein Metrics Inc) show the increasing numbers of DFO (+1 to +8). The respective DARs are shown in red.
View article: Supplementary Table S1 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Table S1 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Table 1. Rank ordering of the anti-TIP1 antibodies based on their KD values
View article: Supplementary Figure S7 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S7 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 7. Biophysical characterization of the purified L111 antibody. A. Analysis of purified L111 antibody integrity by non-reduced (top) and reduced (bottom) capillary electrophoresis-SDS (CE-SDS) on a Perkin Elmer LabChip …
View article: Supplementary Figure S3 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S3 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 3. A. Representative chromatogram showing protein A purification profile of the L111 antibody. B. Representative size exclusion chromatogram in S200 10/300 GL columns of the purified L111 antibody.
View article: Supplementary Figure S5 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S5 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 5. ELISA shows the affinity of purified human anti-TIP1 full-length IgG1 to TIP1 protein. Recombinant TIP1 protein was coated on ELISA plates. Three-fold serial dilutions (starting at 20 nM) of the purified human anti-…
View article: Supplementary Figure S6 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S6 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 6. Flow cytometry evaluation of the purified anti-TIP1 antibodies on H460 (A) and A549 (B) cells. The percentage of anti-TIP1+ vs. antibody concentration was plotted in GraphPad Prism software using One Site-specific b…
View article: Supplementary Figure S10 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S10 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 10. A. In vitro stability of [89Zr]Zr-DFO-L111 antibodies that were either freshly conjugated with DFO or thawed from -80°C after DFO conjugation. The stability was assessed in human serum by instant thin-layer chromat…
View article: Supplementary Table S2 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Table S2 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Table 2. The analysis of the DFO-to-antibody ratio for the D10-L111 by native mass spectrometry
View article: Supplementary Figure S4 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S4 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 4. SDS-PAGE of eight unique purified human anti-TIP1 full-length IgGs under non-reducing (A) and reducing conditions (B). A. Intact full-length IgGs are observed above 150 kDa. B. In the reducing condition, heavy chain…
View article: Supplementary Figure S2 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S2 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 2. A. Colony PCR showing the completeness of the WashU II library. B. Western blots for the WashU II phages at different dilutions were developed with an anti-pIII antibody showing the fused scFv with the pIII coat pro…
View article: Supplementary Figure S4 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Supplementary Figure S4 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library Open
Supplementary Figure 4. SDS-PAGE of eight unique purified human anti-TIP1 full-length IgGs under non-reducing (A) and reducing conditions (B). A. Intact full-length IgGs are observed above 150 kDa. B. In the reducing condition, heavy chain…